QIAGEN N.V.: QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer
(0) The therascreen KRAS RGQ PCR Kit receives U.S. regulatory approval from FDA for expanded scope to include use in guiding treatment with the newly approved therapy LUMAKRAS TM (sotorasib) from Amgen KRAS G12C mutation in NSCLC Test will be available under QIAGEN's Day One Lab Readiness program QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit ( therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identificatio...
Source: finanznachrichten.de
